<p>As the November installment of the Healer webinars unfolded, hosted by renowned cannabis expert Dustin Sulak, DO, attendees delved into recent studies spotlighting cannabis's therapeutic potential across several conditions. The session unraveled fresh insights into how cannabis may benefit individuals with ailments like diabetic neuropathy, chronic back pain, and opioid-induced persistent apnea. The discussion didn't stop there, extending to the potential role of cannabinoids in alleviating Alzheimer's disease symptoms.</p>
<h2 class="pb-4 pt-2 text-2xl">Inhaled Cannabis as a Relief for Diabetic Neuropathy</h2>
<p>One pivotal study presented in the webinar, titled “Long-Term Efficacy and Safety of Inhaled Cannabis Therapy for Painful Diabetic Neuropathy: A 5-Year Longitudinal Observational Study,” highlighted the promising results of cannabis use for managing diabetic neuropathy. Conducted over five years, the study involved 52 patients with painful diabetic neuropathy who had previously exhausted standard treatments. Inhaled medical-grade cannabis, composed of 20% THC and less than 1% CBD, was administered. The findings revealed substantial pain reduction, improved glycemic control, and no significant adverse effects. Although this was an uncontrolled study, Dr. Sulak emphasized the significance of these findings as a promising alternative for individuals unresponsive to conventional therapies.</p>
<h2 class="pb-4 pt-2 text-2xl">The Role of THC in Managing Chronic Low Back Pain</h2>
<p>The spotlight also shone on a decade-long study titled “Long-Term Cannabis Therapy for Chronic Low Back Pain: A 10-Year Prospective Study.” Conducted in Israel, this research involved 168 participants consuming cannabis either through inhalation or edibles, with a mean THC dose tailored to individual needs. Over ten years, patients experienced substantial pain relief and enhanced quality of life, with a notable decline in opioid usage from 91% to a mere 8.2%. Dr. Sulak remarked on the significance of these findings, emphasizing the adaptability of cannabis dosing and its role in personalized medicine, raising the prospect for cannabis as a sustainable alternative to conventional painkillers.</p>
<h2 class="pb-4 pt-2 text-2xl">Exploring CBD's Potential in Preventing Opioid-Induced Apnea</h2>
<p>A groundbreaking study published in Frontiers in Neuroscience examined CBD's potential in counteracting opioid-induced persistent apnea in a rodent model. Traditionally addressed with naloxone, this research unveiled CBD's comparable effectiveness in preventing respiratory suppression caused by fentanyl. Notably, when paired with naloxone, CBD enhanced the median lethal dose of fentanyl in anesthetized mice, suggesting a valuable intervention for individuals using opioids. Dr. Sulak underscored the critical implications of these findings in enhancing opioid safety without compromising their analgesic properties, positioning CBD as a promising adjunctive therapy.</p>
<p>#CannabisNews #CBDTrends #CannabisResearch #THCInsights #CannabisIndustryUpdates</p>